Abstract

The present invention relates to the use of a Lesion Progression Probability Score (LPPS) for predicting the risk of progression of a tumor lesion in a subject suffering from lung cancer when treated by immunotherapy, wherein the tumor lesion comprises a core tumoral region and a peritumoral region referred to as a ring and the LPPS of each lesion comprises 6 specific radiomics features. The invention also relates to the use of a patient progression probability score (PPPS) for predicting the risk of disease progression in a subject suffering from lung cancer when treated by immunotherapy, wherein the PPPS combines the LPPS values of all analyzed tumor lesions of the subject with a volume equal to or higher than a minimum volume Vmin. The invention also relates to therapeutic uses of immunotherapy in subjects with lung cancer with a low or moderate predicted risk of disease progression using the PPPS.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• G06N 3/02 - Neural networks
• G06T 7/00 - Image analysis
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

The present invention is in the field of cancer treatment. It relates to the use of a liver metastasis-specific radiomics-based signature for predicting in a subject suffering from a metastatic cancer with liver metastasis: (a) survival if treated by immunotherapy without preliminary liver focal radiotherapy, (b) response to immunotherapy without preliminary liver focal radiotherapy, (c) survival if treated by liver focal radiotherapy followed by immunotherapy, (d) response to liver focal radiotherapy followed by immunotherapy, or (e) any combination of (a) to (d). It further relates to a method for predicting any one of (a) to (e) based on the same liver metastasis-specific radiomics-based signature, as well as specific therapeutic uses of immunotherapy, with or without previous liver focal radiotherapy, in metastatic cancer subjects with liver metastasis, the selection of the specific treatment being made depending on the same liver metastasis-specific radiomics-based signature.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G06F 18/00 - Pattern recognition
• G06T 7/00 - Image analysis
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• A61B 6/03 - Computed tomography [CT]
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment

Abstract

The present invention relates to serotonin derivatives of general formula (I), and their use in the pharmaceutical field, in particular for preventing or treating metalloptosis associated disorders. The invention also relates to new serotonin derivatives of general formula (I) and their use for preventing or treating iron- and/or copper-associated disorders.

IPC Classes  ?

• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• C07D 209/16 - Tryptamines
• C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The present invention concerns monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein and therapeutic compositions comprising thereof, and in particular their use in the treatment of a mammal suffering from a solid cancer, preferably chosen from cancers resistant to radiation therapy and cancers sensitive to radiation therapy.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a newly identified skin-tropic subset of Tscm that expresses the cutaneous homing marker CLA+. The identification of this new cell population of skin homing Tscm opens up new cell therapy strategies to treat cutaneous diseases, in particular cutaneous cancers such as Merkel cell carcinoma.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system

Abstract

The aim of the invention is to provide an efficient, reliable and accurate method for performing diagnosis, prognosis and/or therapeutic monitoring of diseases impacting the mineral composition of at least one biological fluid. To this end, the method according to the invention essentially consists in - implementing at least one reference database (BDR) containing data relating, on the one hand, to samples of biological fluid, and, on the other hand, to the healthy or diseased subjects from which the samples of biological fluid were taken, these data comprising for each sample: (i) at least one mineral profile PM of concentrations of mineral elements in the biological fluid and (ii) conventional clinical data on the subjects; -implementing at least one sample Ex of biological fluid of at least one subject Sx to be tested; - analyzing each sample to determine at least one PM of Sx; - defining at least two categories with a view to making at least one prediction of membership of the subject Sx to be tested to at least one category of diagnosis (d), prognosis (p) and/or therapeutic monitoring (t), and, optionally to at least one subdivision of at least one category; - statistically processing the data of the BDR and displaying the processed data graphically, then positioning the data relating to Sx on this graphical display; - and/or carrying out AI-based machine learning using the data of the BDR; in order to make the prediction of membership regarding Sx and assist, by so doing, with the diagnosis, prognosis and/or therapeutic monitoring of diseases impacting the mineral composition of at least one biological fluid, for the subject Sx to be tested. The invention also relates to an electronic device, to a system for implementing the method, and to at least one computer program (and its medium) for executing the method.

IPC Classes  ?

• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

The present invention relates to the field of oncology. It more particularly relates to a method for evaluating the prognosis or the response to a therapeutic treatment of a subject having a squamous cell carcinoma by assessing the multinucleated giant cells status of a SCC tumor of the subject. This method may be advantageously computer-implemented for ease of use in the clinic.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to the treatment of locally advanced and metastatic muscle-invasive bladder cancers (MIBC). The present invention provides compositions to be used in immunotherapy of MIBC, especially in combination with an anti-PD-1/PD-L1/PD-L2 antibody-based therapy. The present invention also provides biomarkers of response to anti-PD-1/PD-L1/PD-L2 immune checkpoint blocking antibodies (ICBs), alone or together with anti-CTLA4 antibodies and/or chemotherapy, for best guiding their neoadjuvant use and avoid unefficient administration of potentially toxic drugs to patients with localized bladder cancers.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a liquid pharmaceutical composition comprising totally dissolved arsenic trioxide, at least one solubilizing agent selected from the metal-alkali acetates and metal-alkali lactates, and a solvent system which comprises a non-ionic surfactant and propylene glycol. The invention also relates to pharmaceutical capsule comprising the liquid composition of the invention. The invention further relates to said liquid pharmaceutical composition or said pharmaceutical capsule for use in the treatment of cancer or autoimmune diseases.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 33/36 - ArsenicCompounds thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the field of oncology, in particular cellular therapy. The present invention more particularly relates to particular immune cells defective for ZNF217, products comprising such defective cells, and uses thereof.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]

Abstract

The present disclosure provides improved methods, therapeutic regimens, and systems for treating a disease associated with a pituitary malignancy in a subject, such as treating Cushing Syndrome, or treating one or more symptoms of Cushing Syndrome in subjects, through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods. The present disclosure also relates to compositions for use and methods in treating synovial inflammation in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression. The present disclosure also relates to compositions for use and methods in treating degenerative joint disease, joint inflammation, and manifestations thereof in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 5/00 - Drugs for disorders of the endocrine system
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a method for determining the irradiation dose that has been or will be received by a lymphocyte L during a radiotherapy treatment performed on a target organ of a patient, said method comprising the steps of: a) collecting the following data associated to said radiotherapy treatment: - the radiation treatment planning applied to or scheduled for said patient, - the radiation reference doses applied to or scheduled for said patient, and - the number, location and volume of the lymphoid organs that have been or will be irradiated (if any), b) simulating the lymphocyte path between the several organs of the body, c) determining the irradiation dose received by said lymphocyte L during said radiotherapy treatment would it be circulating in peripheral blood, or present in or circulating between lymphoid organs, d) optionally, determining the irradiation dose received by at least one out-of-field lymphoid organ during said radiotherapy treatment, e) combining these data in order to determine the irradiation dose that has been or will be received by the lymphocytes of said patient during said radiotherapy treatment.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

A method for treating chronic myelomonocytic leukemia (CMML), or for maintaining or enhancing the proliferation of wildtype hematopoietic stem cells in patients suffering from CMML, by administering to a patient in need thereof a pharmaceutical composition containing an effective amount of an inhibitor of the CXCL8 receptor.

IPC Classes  ?

• A61K 31/18 - Sulfonamides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/02 - Antineoplastic agents specific for leukemia
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention concerns new oncolytic viruses and their uses In particular, the invention is a viral particle for its use in the prevention and/or the treatment of a tumor, said viral particle comprising: an inactivated nucleic acid sequence encoding the native envelope glycoprotein of the IROV encoded by said IROV genome; and a nucleic acid sequence encoding a retroviral envelope glycoprotein or a fragment thereof having a native targeting capacity for said host cell surface protein.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors
• A61P 35/00 - Antineoplastic agents
• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus

Abstract

The present invention is based on the demonstration that bacteria of the Akkermansia genus improve the response to CAR T-cells therapy. According to the invention, Akkermansia bacteria are administered to patients treated with CAR T-cells, especially if their gut microbiome was devoid of such bacteria before administering said CAR T-cells.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens

Abstract

The present invention relates to a method of predicting assessing or monitoring the sensitivity of a subject having a cancer to a combination therapy, preferably to a therapy combining an immunotherapeutic agent and an anti-angiogenic agent, and to corresponding kits and uses thereof. The method of predicting, assessing or monitoring the sensitivity of a subject having a cancer or malignant tumor to a proposed combination therapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level or proportion of at least one biomarker, for example at least two biomarkers, and when the expression level or proportion is determined a step b) of comparing said expression level or proportion to reference expression level(s) or to reference expression ratio(s), thereby predicting, assessing or monitoring whether the subject having a tumor is responsive or resistant to the proposed combination therapy.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Abstract

The present invention relates to method for medical imaging, the method being characterized in that it comprises the implementation, by a data processor (11b) of a second server (1b), of steps of: (a) Obtaining at least one candidate pre-contrast image and a candidate contrast image respectively depicting a body part prior to and after an injection of a first dose of contrast agent, wherein said first dose is higher than a predetermined low dose, the predetermined reduced dose being lower than a predetermined standard dose; a convolutional neural network, CNN, being trained to reconstruct, from at least a pre-contrast input image and a low dose contrast input image respectively depicting a body part prior to and after an injection of said low dose of contrast agent, a standard dose contrast image depicting said body part after an injection of said standard dose of contrast agent; (b) Simulating an injection of a second dose of contrast agent which is higher than the standard dose, wherein said simulating comprises generating a synthetic contrast image by applying the CNN to the at least one candidate pre-contrast image and the candidate contrast image.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• G06T 11/00 - 2D [Two Dimensional] image generation
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

The present invention relates to a new and specific T-cell therapy strategy based on the use of memory stem T-cells (Tscm), in particular highly functional memory stem T-cells (Tscm) negatively selected on the basis of inhibitory receptor expression. This new cellular immunotherapy may be applied to PML patients but also to other infections or cancers for which the specific memory T cell responses are functionally impaired.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to a method of predicting, assessing or monitoring the sensitivity of a subject having a cancer to an immunotherapy, preferably to an immunotherapy combining at least two immunotherapeutic agents, and to corresponding kits and uses thereof. The method of predicting, assessing or monitoring the sensitivity of a subject having a tumor to an immunotherapy typically comprises a step of assessing, before any immunotherapeutic treatment step in the subject, the presence of CD4+CD25highCD39high T cells in a tumor sample of the subject, the presence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of sensitivity of the subject to the immunotherapy, and the absence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of resistance of the subject to the immunotherapy.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure relates to methods for treating radioactive contamination, in particular internal radioactive contamination, said method comprising orally administering, in a subject at risk or suspected of radioactive contamination, an efficient amount of a functionalized polymer, wherein said functionalized polymer is a specific statistic chitosan polymer wherein a part of the monomeric units are functionalized with a chelating moiety which complexes said radionuclide.

IPC Classes  ?

• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61P 39/04 - Chelating agents
• A61P 39/06 - Free radical scavengers or antioxidants

Abstract

The present invention relates to a new drug conjugate comprising a CTLA4 targeting molecule, at least one cytotoxic agent, and a linker connecting the CTLA4 targeting molecule and the cytotoxic agent, as well as to compositions and kits comprising such a drug conjugate, and to uses thereof in particular for treating cancer and/or for preventing a cancer relapse in a subject in need thereof.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to the field of anticancer treatment. In particular, the present invention concerns the role of the gut microbiota in the efficacy of immune checkpoints inhibitors (ICI)-based treatments and provides methods for determining if a patient is likely to benefit from an ICI-based treatment, more precisely, treatment comprising administration of an antibody directed against PD1 or PD-L1. The present invention provides a method for stratifying cancer patients according to their potential need of bacterial complementation before receiving an ICI-based treatment. The present invention also provides a simple method for determining whether an individual has an intestinal dysbiosis.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/24 - MucusMucous glandsBursaSynovial fluidArthral fluidExcretaSpinal fluid
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell lymphoma affects lymph nodes and extra-nodal sites with characteristic skin lesions. Approximatively half of the tumors express the NPM1-ALK fusion from the translocation t(2;5)(p23;q32). In the present study, the inventors identify ROR2 as progressively up regulated thought tumorigenesis. Patient samples show a significantly high ROR2 expression (transcriptomic data) as well as a strong ROR2 protein expression (IHC) with some tumors displaying a clear membrane signal. ROR2 mRNA expression level is also positively correlated to NPM-ALK expression level in tumor cells and is not expressed in normal T cells. In addition, ROR2 protein level is significantly increased in resistant cells to the ALK inhibitor, crizotinib, used in clinical trials for children with refractory tumors. This result opens the road to ROR2 specific therapies: ROR2 inhibitors, monoclonal antibodies therapies or even ROR2 specific CAR cells, including for ALCL ALK(+) resistant tumors.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The disclosure relates to a method of treating cancer in a subject in need thereof, said method comprising (i) a priming phase, and (ii) a treatment phase, wherein said priming phase comprises administering an efficient amount of said nanoparticles in combination with a low-dose radiotherapy, and said treatment phase comprises administering an efficient amount of said nanoparticles in combination with radiotherapy, optionally in combination with an immune checkpoint blocker, wherein said nanoparticles are nanoparticles containing an element with an atomic Z number higher than 20, preferably higher than 50, for example between 40 and 83, more preferably gadolinium or bismuth.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents
• A61K 103/34 - Gadolinium

Abstract

The present invention relates to novel serotonin derivatives of formula (I): The present invention relates to novel serotonin derivatives of formula (I): The present invention relates to novel serotonin derivatives of formula (I): or a pharmaceutically acceptable salt and/or solvate thereof. The present invention relates to novel serotonin derivatives of formula (I): or a pharmaceutically acceptable salt and/or solvate thereof. Another object of the present invention relates to the use of compound of formula (I) as a drug, in particular in the prevention and/or the treatment of iron overload-associated disorders.

IPC Classes  ?

• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61P 7/06 - Antianaemics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 209/16 - Tryptamines
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to a new and specific T-cell therapy strategy based on the use of memory stem T-cells (Tscm). This new cellular immunotherapy may be applied to PML patients but also to other infections or cancers for which the specific memory T cell responses are functionally impaired.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The invention pertains to isolated population of tumor-associated macrophage cell populations, their use in prognosing the malignancy and the outcome of solid tumors, as well as compounds which inhibit the expression of certain genes in these macrophage cells, in tumor-associated macrophage populations, for use for treating a solid cancer in a subject in need thereof.

IPC Classes  ?

• C12N 5/0786 - MonocytesMacrophages

Abstract

The present disclosure provides improved methods, compositions, agents, therapeutic regimens, and systems for cancer treatment, such as improving the outcome of chemo- and/or immunotherapies, and/or inducing autophagy in subjects through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods.

IPC Classes  ?

• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

A liquid pharmaceutical composition comprising an aqueous solvent, nicotinamide and at least one imipridone derivative of formula (I). A process for manufacturing said liquid pharmaceutical composition, wherein the process comprises the steps of (a) Dissolving nicotinamide in an aqueous solvent, preferably water; (b) Adding at least one pH modifier and at least one imipridone derivative to the solution obtained in step (a); and (c) Optionally sterilizing the solution obtained in step (b). A 1: 1 imipridone derivative nicotinamide complex or cocrystal, wherein the imipridone derivative is of formula (I). Said compositions for use in the treatment of cancer.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

The present invention relates to adenosine deaminase 1 (ADAR1) inhibitors for use in a method of treating an individual with a homologous recombination defective (HRD) cancer, as well as methods for selecting individuals suitable for such treatments.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides tools for stratifying patients suffering from osteosarcoma, in order to identify patients having poor prognosis tumors. The invention also pertains to the use of an inhibitor of the PPARγ pathway as an antineoplastic treatment to improve the overall survival of patients with a poor prognosis osteosarcoma.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the field of anticancer immunotherapy. In particular, the present invention concerns the role of the MAdCAM-1/α4β7 axis the gut microbiota in the efficacy of cancer treatments and provides methods for determining if a patient is likely to benefit from a cancer treatment, more precisely, and immuno-oncology (I-O) therapy, such as a treatment comprising administration of an antibody directed against immune checkpoint blockers PD1, PD-L1 or PD-L2 alone or together with CTLA4 and/or chemotherapy. The present invention also provides methods to improve the efficacy of such a treatment in patients in need thereof.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to compounds capable of inducing autophagy and metabolic reprogramming and to the use thereof as cardioprotectors, in particular in the context of anticancer therapy.

IPC Classes  ?

• A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers

Abstract

The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.

IPC Classes  ?

• A61K 35/66 - Microorganisms or materials therefrom
• A61K 35/741 - Probiotics
• A61P 35/00 - Antineoplastic agents
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

A method implemented by computer means for training a decision system for segmenting medical images from a training set of annotated medical images, the segments belonging to at least one class, each annotation of the medical images including quantitative information about a number of pixels of the image that belongs to each of the classes, the method using weakly-supervised algorithm based on a percentage of the pixels of the image belonging to a concerned class.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Goods & Services

Media for recording, transmitting, reproducing and duplicating sound, data or images; data media [electric or electronic]; pre-recorded or blank video cassettes and video disks, pre-recorded or blank laser cassettes and laser discs, magnetic tape cassettes and sound recording discs, sound and audiovisual recordings; audio digital compact disks, video disks, optical disks; magnetic cards; memory cards or integrated circuit cards; magnetic and electronic pens; computer programs, software on all types of material carriers, software for generating virtual images, databases, text and sound data banks, image banks; data downloadable on a computer or a portable telephone and particularly ringtones, sounds, music, photographs, videos, images, logos, texts and any other content; electronic publications and downloadable electronic publications particularly via an international telecommunication network; Downloadable digital files authenticated by non-fungible tokens [NFTs]. Printing products (printed matter); bookbinding material; photographs; stationery; instructional or teaching material (except apparatus); writing or drawing books; notepads; notebooks; printing blocks; paper; cardboard; boxes of cardboard or paper; pens and pen refills, pencils; pencil sharpeners; posters; posters; printed matter; albums; cards; writing paper; files; folders for papers; labels, not of textile; stickers and transfers [decalcomanias]; drawing pads; books; newspapers and periodicals; handouts; magazines; journals (magazines); publications; atlases; newsletters; catalogs; prospectuses; pamphlets; calendars; diaries (planners); writing instruments; drawings; face towels of paper; bags and small bags (envelopes, pouches) of paper or plastic for packaging; specialized journals in the medical field. Ribbons and braid, pins; ornamental novelty badges; hair bands; brassards; competitors' numbers; elastic ribbons. Advertising; dissemination of advertising material (leaflets, prospectuses, printed matter, samples, free CD-ROMs); rental of advertising space, updating of advertising documents; dissemination of advertisements, media planning services; subscription to a telephone information services; subscriptions to a global telecommunications network (the Internet) or a private access network (intranet); subscription services to a multimedia or database server center; subscription service to a database; subscriptions to electronic newspapers; newspaper subscription services for others; administrative management of a platform for hosting and exchanging data, images, sounds, sound and/or video recordings, videos; administrative management of a database on the Internet; services for inputting, editing, compiling and processing data and more generally for recording, transcribing and systematizing written communications and sound and/or image recordings; collection and systematization of data in a central file; data search in computer files for others; assistance and business management assistance for non-commercial entities; computer file management for others; recording, composition, systematization of data written or received by computer, and particularly data communication or remote computing; public relations; organization of trade fairs and exhibitions for advertising purposes; organization of competitions in connection with advertising; online advertising on a computer network; administrative management on behalf of non-commercial entities, including organizations and foundations; business assistance and management and administrative services, namely, advice, information and inquiries for the management of non-commercial entities, including associations and foundations, management assistance for associations and foundations; consulting, information or inquiries in connection with associations in the conduct of their activities, namely consulting, information or inquiries for associations in the field of administration and accounting; conducting of online virtual trade fairs; networking services with bloggers; advertising and marketing services provided by means of blogging; retail service for downloadable digital files authenticated by non-fungible tokens [NFTs]. Investing and managing funds; financing services for the publication and transmission of information relating to science, medicine, in particular for medical research; financial consultancy for projects in the field of science and medicine, particularly for medical research; charitable fundraising; mutual funds; collection and distribution of donations for business associations and companies; funding studies and evaluations in the field of patronage; raising capital; financial transactions; sponsorship and financial assistance to and from companies, associations, non-governmental organizations or special programs in particular in the field of medical research; advice, information or inquiries to associations on financial matters and fiscal valuations. Education; training; sporting and cultural activities; information relating to entertainment or education; publication of books; videotape film production; organization of competitions (education or entertainment); organization and conducting of colloquiums, conferences or congresses; organization of exhibitions for cultural or educational purposes; organization and conducting of award ceremonies, concerts, fashion shows, charity galas; production and organization of shows; booking of theater halls; education and entertainment; organization of information campaigns (for cultural or educational purposes) or professional or other events (excluding commercial or advertising events); organization and conducting of training workshops, practical training, editing and publishing of books and any kind of sound and/or visual media, recording, transmission and reproduction of sound and/or images (except advertising matter); editing and publishing of multimedia carriers; book lending; electronic publication of downloadable and non-downloadable books and periodicals online; publishing of texts, illustrations, newspapers, magazines, periodicals and more generally of all publications other than advertising texts, including electronic and digital publications, including electronic and digital books; correspondence courses; film production, video production; advice, information or inquiries to associations on culture and art matters; editing of medical publications; publication of scientific articles relating to medical technology; organization of conferences and symposiums in the field of medical science; provision of online training seminars; providing online colloquiums, conferences or congresses, exhibitions for cultural or educational purposes; entertainment services, namely, providing virtual environments in which users can interact for recreational, leisure or entertainment purposes; entertainment services, namely, organization and hosting of virtual shows and social entertainment events.

Abstract

The present invention proposes an efficient method to prognose the evolution of a solid cancer in a subject in need thereof, by analysing the frequency of a particular subset of dendritic cells as well as their relative number as compared to that of another subset of dendritic cells in a tumour sample of said subject. More precisely, the method of the invention comprises the step of detecting and quantifying the frequency of CD207+conventional dendritic cells of type 2 and 3 ("CD207+DC2+DC3") in a tumour sample of said subject. If the frequency of said cells is high, in particular in the tumour core, then it means that the subject has a bad prognosis. The method of the invention also comprises the calculation within the tumour of the ratio of the number of conventional dendritic cells of type 1 (cDC1) to the number of CD207+DC2+DC3 to predict T-cell clonality in the tumour. As a matter of fact, the inventors herein establish that the CD207+DC2+DC3 participate in the regulation of the anti-tumour T-cell cytotoxicity by limiting T-cell clonality and impairing the CD8+tissue resident memory T cell (TRM) response. Their analysis furthermore reveals that the CD207+ DC2+DC3 are enriched in biopsies from later deceased patients as compared to alive patients suffering from different solid cancers. The inventors also propose to reduce the abundance of these cells within the tumour core, e.g., by appropriate drugs, in order to limit the development of said solid tumour in the subject.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Goods & Services

Media for recording, transmitting, reproducing and duplicating sound, data or images; data media [electric or electronic]; pre-recorded or blank video cassettes and video disks, pre-recorded or blank laser cassettes and laser discs, magnetic tape cassettes and sound recording discs, sound and audiovisual recordings; audio digital compact disks, video disks, optical disks; magnetic cards; memory cards or integrated circuit cards; magnetic and electronic pens; computer programs, software on all types of material carriers, software for generating virtual images, databases, text and sound data banks, image banks; data downloadable on a computer or a portable telephone and particularly ringtones, sounds, music, photographs, videos, images, logos, texts and any other content; electronic publications and downloadable electronic publications particularly via an international telecommunication network; downloadable digital files authenticated by non-fungible tokens [NFTs]. Printing products (printed matter); bookbinding material; photographs; stationery; instructional or teaching material (except apparatus); writing or drawing books; notepads; notebooks; printing blocks; paper; cardboard; boxes of cardboard or paper; pens and pen refills, pencils; pencil sharpeners; posters; posters; printed matter; albums; cards; writing paper; files; folders for papers; labels, not of textile; stickers and transfers [decalcomanias]; drawing pads; books; newspapers and periodicals; handouts; magazines; journals (magazines); publications; atlases; newsletters; catalogs; prospectuses; pamphlets; calendars; diaries (planners); writing instruments; drawings; face towels of paper; bags and small bags (envelopes, pouches) of paper or plastic for packaging; specialized journals in the medical field. Ribbons and braid, pins; ornamental novelty badges; hair bands; brassards; competitors' numbers; elastic ribbons. Advertising; dissemination of advertising material (leaflets, prospectuses, printed matter, samples, free CD-ROMs); rental of advertising space, updating of advertising documents; dissemination of advertisements, media planning services; subscription to a telephone information services; subscriptions to a global telecommunications network (the Internet) or a private access network (intranet); subscription services to a multimedia or database server center; subscription service to a database; subscriptions to electronic newspapers; newspaper subscription services for others; administrative management of a platform for hosting and exchanging data, images, sounds, sound and/or video recordings, videos; administrative management of a database on the Internet; services for inputting, editing, compiling and processing data and more generally for recording, transcribing and systematizing written communications and sound and/or image recordings; collection and systematization of data in a central file; data search in computer files for others; assistance and business management assistance for non-commercial entities; computer file management for others; recording, composition, systematization of data written or received by computer, and particularly data communication or remote computing; public relations; organization of trade fairs and exhibitions for advertising purposes; organization of competitions in connection with advertising; online advertising on a computer network; administrative management on behalf of non-commercial entities, including organizations and foundations; business assistance and management and administrative services, namely, advice, information and inquiries for the management of non-commercial entities, including associations and foundations, management assistance for associations and foundations; consulting, information or inquiries in connection with associations in the conduct of their activities, namely consulting, information or inquiries for associations in the field of administration and accounting; conducting of online virtual trade fairs; networking services with bloggers; advertising and marketing services provided by means of blogging; retail service for downloadable digital files authenticated by non-fungible tokens [NFTs]. Investing and managing funds; financing services for the publication and transmission of information relating to science, medicine, in particular for medical research; financial consultancy for projects in the field of science and medicine, particularly for medical research; charitable fundraising; mutual funds; collection and distribution of donations for business associations and companies; funding studies and evaluations in the field of patronage; raising capital; financial transactions; sponsorship and financial assistance to and from companies, associations, non-governmental organizations or special programs in particular in the field of medical research; advice, information or inquiries to associations on financial matters and fiscal valuations. Education; training; sporting and cultural activities; information relating to entertainment or education; publication of books; videotape film production; organization of competitions (education or entertainment); organization and conducting of colloquiums, conferences or congresses; organization of exhibitions for cultural or educational purposes; organization and conducting of award ceremonies, concerts, fashion shows, charity galas; production and organization of shows; booking of theater halls; education and entertainment; organization of information campaigns (for cultural or educational purposes) or professional or other events (excluding commercial or advertising events); organization and conducting of training workshops, practical training, editing and publishing of books and any kind of sound and/or visual media, recording, transmission and reproduction of sound and/or images (except advertising matter); editing and publishing of multimedia carriers; book lending; electronic publication of downloadable and non-downloadable books and periodicals online; publishing of texts, illustrations, newspapers, magazines, periodicals and more generally of all publications other than advertising texts, including electronic and digital publications, including electronic and digital books; correspondence courses; film production, video production; advice, information or inquiries to associations on culture and art matters; editing of medical publications; publication of scientific articles relating to medical technology; organization of conferences and symposiums in the field of medical science; provision of online training seminars; providing online colloquiums, conferences or congresses, exhibitions for cultural or educational purposes; entertainment services, namely, providing virtual environments in which users can interact for recreational, leisure or entertainment purposes; entertainment services, namely, organization and hosting of virtual shows and social entertainment events.

Abstract

The invention provides a pharmaceutical composition in oral liquid form, comprising vinorelbine, or a pharmaceutically acceptable salt thereof, and a cyclodextrin that is sulfobutylether-beta-cyclodextrin (SBE-beta-CD), preferably wherein at least 95%, vinorelbine, or said pharmaceutically acceptable salt thereof, is in form of an inclusion complex with said cyclodextrin.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/08 - Solutions
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present disclosure relates to a functionalized polymer, for use in treating a disease correlated with heavy metal-induced toxicity or heavy metal-induced carcinogenicity in a subject in need thereof, wherein said functionalized polymer is soluble in aqueous solution, has a weight average molecular mass between 30 kDa and 5000 kDa, and wherein a part of the monomeric units are functionalized with a chelating moiety, wherein therapeutically efficient amount of said functionalized polymer is administered orally to the subject.

IPC Classes  ?

• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 31/718 - Starch or degraded starch, e.g. amylose, amylopectin
• A61K 31/722 - ChitinChitosan
• A61P 35/00 - Antineoplastic agents
• A61P 39/04 - Chelating agents
• A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides

Abstract

Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA binding protein (ACBP)/diazepam binding inhibitor (DBI) reduces the deleterious effect of the anthracycline doxorubicin on cardiac function. Since anthracycline-induced heart failure and anthracycline-induced senescence are models of accelerated cardiac aging, it is also plausible to use ACBP/DBI inhibition or neutralization as a method to prevent or treat aging of the cardiovascular system. The inventors also found that genetic and pharmacological interventions to deplete ACBP/DBI efficiently improves cardiac dysfunction associated with experimental HFpEF, a condition associated with aging, hypertension and obesity. Accordingly, the present disclosure relates to methods for the treatment of cardiac dysfunction comprising neutralization of ACBP/DBI.

IPC Classes  ?

• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention concerns a novel in vitro assay for determining the invasive ability of brain tumour cells, in particular brain tumour stem cells. This new assay, called 3D invasion assay, is based on the analysis and comparison of the area of neurospheres grown in vitro into a Matrigel extracellular-like matrix. The invention also concerns the use of said assay for diagnosing metastatic brain tumour in subjects, for determining its prognosis, as well as for the monitoring, for the stratification, for identifying subjects at risk of metastasis, and/or predicting the metastasis-associated risk in subjects diagnosed with brain tumour.

IPC Classes  ?

• C12N 5/095 - Stem cellsProgenitor cells
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to serotonin derivatives of general formula (I), and their use in the pharmaceutical field, in particular for preventing or treating metalloptosis associated disorders. The invention also relates to new serotonin derivatives of general formula (I) and their use for preventing or treating iron- and/or copper-associated disorders.

IPC Classes  ?

• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61P 7/06 - Antianaemics
• C07D 209/00 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

Abstract

Cardiovascular diseases represent the leading cause of mortality and accounts for approximately one-third of deaths globally each year. During the last decade, tremendous efforts have been made to take advantage of advances in regenerative cardiology using the approaches of adult or pluripotent stem cells. However, the current protocols do not recapitulate cardiac-related architectures. Thus, there remains a need in the art for further methods for producing cardiac organoids actually mimicking a cardiac tissue, starting from pluripotent stem cells. Notably, there remains a need in the art for producing cardiac organoids comprising cardiac muscle cells and endothelial cells, including both atrium-like and ventricular-like chambers. Such cardiac organoids that reliably mimic a cardiac tissue would notably allow testing for the physiological effects of known drug substances as well as candidate molecules, particularly in embodiments wherein the said cardiac organoids are produced by starting from cells originating from patients affected with a cardiac disease or disorder such as a cardiac disease or disorder of genetic origin. It is now provided a novel matrix-free and feeder-free method of generating mammal iPSC-derived cardiac organoids, which method includes both steps of dynamic culture conditions and static culture conditions. As it is experimentally shown, cardiac organoids obtained with the matrix-free and feeder-free method disclosed herein are relevant models for testing potentially active substances on cardiac organoids obtained from iPSCs derived from subjects affected with a cardiac disease or disorder.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention relates to a microcapsule that is made of bioavailable polymer, is loaded with at least one active substance and comprises at least one micrometric opening. The invention also relates to a method for obtaining said capsule and to said capsule for use in the treatment of a pathology, in particular cancer or myopathy.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The inventors herein show that purinergic receptors regulate the conversion of macrophage pro-inflammatory reprogramming into anti-inflammatory phenotype in patients suffering from COVID-19 disease. Moreover, they show that P2Y receptor agonists repress NLRP3 inflammasome-dependent IL-1b secretion, but also impair the replication and the cytopathogenic effects of SARS-CoV-2. These results therefore suggest that some purinergic receptors agonists can treat acute lung injury and respiratory disease that are associated with SARS-CoV-2 infection. In addition, their results show that antagonists of the purinergic receptors P2X impair the replication of said virus. The present invention therefore proposes to use purinergic receptors modulators and NLR3-P2Y2R immune checkpoint modulators to treat patients suffering from a virus-induced acute respiratory distress syndrome.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid

Abstract

The present invention relates to the treatment of locally advanced and metastatic muscle-invasive bladder cancers (MIBC). The present invention provides compositions to be used in immunotherapy of MIBC, especially in combination with an anti-PD-1/PD-L1/PD-L2 antibody-based therapy. The present invention also provides biomarkers of response to anti-PD- 1/PD-L1/PD-L2 immune checkpoint blocking antibodies (ICBs), alone or together with anti-CTLA4 antibodies and/or chemotherapy, for best guiding their neoadjuvant use and avoid unefficient administration of potentially toxic drugs to patients with localized bladder cancers.

IPC Classes  ?

• A61K 39/07 - Bacillus
• A61K 39/085 - Staphylococcus
• A61K 39/108 - EscherichiaKlebsiella
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/116 - Polyvalent bacterial antigens
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial

Abstract

E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The present disclosure relates to the field of nanomedicine, in particular for treating cancers. The present disclosure more specifically provides new methods of treating undesirable M2-polarized macrophages and/or inducing M1 macrophage polarization in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of nanoparticles containing metallic elements.

IPC Classes  ?

• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to a method for identifying compounds useful for the treatment of cancer based on assessing the ability of the compound to modulate the interaction between the AIF protein and the CHCHD4 protein.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 19/00 - Hybrid peptides
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.

IPC Classes  ?

• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to method for medical imaging, the method being characterized in that it comprises the implementation, by a data processor (11b) of a second server (1b), of steps of: (a) Obtaining at least one candidate pre-contrast image and a candidate contrast image respectively depicting a body part prior to and after an injection of a first dose of contrast agent, wherein said first dose is higher than a predetermined low dose, the predetermined reduced dose being lower than a predetermined standard dose; a convolutional neural network, CNN, being trained to reconstruct, from at least a pre-contrast input image and a low dose contrast input image respectively depicting a body part prior to and after an injection of said low dose of contrast agent, a standard dose contrast image depicting said body part after an injection of said standard dose of contrast agent; (b) Simulating an injection of a second dose of contrast agent which is higher than the standard dose, wherein said simulating comprises generating a synthetic contrast image by applying the CNN to the at least one candidate pre-contrast image and the candidate contrast image.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

The present invention relates to the field of medical devices, more particularly the field of devices for extracting circulating molecules from the blood of a mammal, and their therapeutic uses, in particular in treating sepsis, cytokine release syndrome and/or any other form of systemic inflammatory response or cytokine shock, caused by bacterial, parasitic, fungal or viral infections, in particular caused by a viral infection, for example coronaviruses with human respiratory tract tropism.

IPC Classes  ?

• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes

Abstract

The present invention relates to a method of predicting assessing or monitoring the sensitivity of a subject having a cancer to an immunotherapy, preferably to an immunotherapy combining at least two immunotherapeutic agents, and to corresponding kits and uses thereof. The method of predicting, assessing or monitoring the sensitivity of a subject having a tumor to an immunotherapy typically comprises a step of assessing, before any immunotherapeutic treatment step in the subject, the presence of CD4+CD25highCD39high T cells in a tumor sample of the subject, the presence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of sensitivity of the subject to the immunotherapy, and the absence of CD4+CD25highCD39high T cells in the tumor sample of the subject being indicative of resistance of the subject to the immunotherapy.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a new and specific T-cell therapy strategy based on the use of memory stem T-cells (Tscm), in particular highly functional memory stem T-cells (Tscm) negatively selected on the basis of inhibitory receptor expression. This new cellular immunotherapy may be applied to PML patients but also to other infections or cancers for which the specific memory T cell responses are functionally impaired.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to methods and compositions for the care of breast cancer, from diagnosis to treatment management. The inventors show that LINC01087 downregulation contributes to a more aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of triple-negative breast cancer. The inventors show that LINC01087 upregulation contributes to a less aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of luminal BCs. The invention relates to a method comprising the steps of: i) determining the expression level of the long intergenic non-coding RNA 01087 (LINC01087) in a sample obtained from the subject, and ii) comparing the expression level determined at step i) with a predetermined reference value, wherein detecting difference between the expression level determined at step i) and the predetermined reference value is indicative of an aggressive TNBC or less aggressive luminal BCs.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to novel serotonin derivatives of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. Another object of the present invention relates to the use of compound of formula (I) as a drug, in particular in the prevention and/or the treatment of iron overload-associated disorders.

IPC Classes  ?

• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61P 7/06 - Antianaemics
• C07D 209/16 - Tryptamines

Abstract

A freeze-dried powder for preparing a thermogel including: from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; from 40% to 85% of one or more poloxamer; and from 0.1% to 20% of one or more carbohydrate compound.

IPC Classes  ?

• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/06 - OintmentsBases therefor

Abstract

The present invention relates to the field of anticancer immunotherapy. In particular, the present invention concerns the role of the MAdCAM-1/α4β7 axis the gut microbiota in the efficacy of cancer treatments and provides methods for determining if a patient is likely to benefit from a cancer treatment, more precisely, and imuno-oncology (l-O) therapy, such as a treatment comprising administration of an antibody directed against immune checkpoint blockers PD1, PD-L1 or PD-L2 alone or together with CTLA4 and/or chemotherapy. The present invention also provides methods to improve the efficacy of such a treatment in patients in need thereof.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention pertains to the use of bacteria selected amongst Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum for inducing immunostimulation in a patient in combination with an anti-cancer immunotherapy with an immune checkpoint inhibitor (ICI) and/or a tyrosine kinase inhibitor (TKI). The invention also relates to methods for assessing the probability that a patient respond to a treatment with an ICI and/or a TKI, based on measuring the relative abundances of immunotolerant bacterial species (Clostridium hathewayi, Clostridium clostridioforme and Clostridium boltae) and/or immunostimulatory bacterial species (Akkermansia muciniphila, Bacteroides salyersiae, Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum) in the patient's gut microbiota.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 35/00 - Antineoplastic agents
• A61K 35/741 - Probiotics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 9/22 - Ribonucleases
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/47 - QuinolinesIsoquinolines

Abstract

The application pertains to biomarkers for assessing whether an individual is likely to resist to an infection by a SARS-CoV-2 virus or is susceptible to SARS-CoV-2.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The invention relates to compounds capable of inducing autophagy and metabolic reprogramming and to the use thereof as cardioprotectors, in particular in the context of anti-cancer therapy.

IPC Classes  ?

• A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 35/00 - Antineoplastic agents
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 39/00 - General protective or antinoxious agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell lymphoma affects lymph nodes and extra-nodal sites with characteristic skin lesions. Approximatively half of the tumors express the NPM1-ALK fusion from the translocation t(2;5)(p23;q32). In the present study, the inventors identify ROR2 as progressively up regulated thought tumorigenesis. Patient samples show a significantly high ROR2 expression (transcriptomic data) as well as a strong ROR2 protein expression (IHC) with some tumors displaying a clear membrane signal. ROR2 mRNA expression level is also positively correlated to NPM-ALK expression level in tumor cells and is not expressed in normal T cells. In addition, ROR2 protein level is significantly increased in resistant cells to the ALK inhibitor, crizotinib, used in clinical trials for children with refractory tumors. This result opens the road to ROR2 specific therapies: ROR2 inhibitors, monoclonal antibodies therapies or even ROR2 specific CAR cells, including for ALCL ALK(+) resistant tumors.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The invention relates to a method implemented by computer means for training a decision system for segmenting medical images (6) from a training set of annotated medical images, said segments belonging to at least one class, each annotation (LB) of said medical images including quantitative information about a number of pixels of the image (6) that belongs to each of said classes, said method using weakly-supervised algorithm based on a percentage of the pixels of said image belonging to a concerned class.

IPC Classes  ?

• G06N 3/08 - Learning methods
• G06N 20/00 - Machine learning
• G06N 3/04 - Architecture, e.g. interconnection topology

Abstract

Identification of effective targets alleviating the programmed cell removal (PrCR) of tumor cells by macrophages is of very high interest. The present inventors have identified that the cyclin-dependent kinase inhibitor p21 protein is a strong regulator of the macrophage-mediated PrCR. Also, they showed that the adoptive transfer of p21 overexpressing monocytes induces macrophage PrCR and transition from an anti-inflammatory to a pro-inflammatory phenotype in vivo, delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 5/0786 - MonocytesMacrophages
• C12N 15/86 - Viral vectors
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to the field of anticancer treatment. In particular, the present invention concerns the role of the gut microbiota in the efficacy of immune checkpoints inhibitors (ICI)-based treatments and provides methods for determining if a patient is likely to benefit from an ICI-based treatment, more precisely, treatment comprising administration of an antibody directed against PD1 or PD-L1. The present invention provides a method for stratifying cancer patients according to their potential need of bacterial complementation before receiving an ICI-based treatment. The present invention also provides a simple method for determining whether an individual has an intestinal dysbiosis.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 35/741 - Probiotics

Abstract

The present invention provides tools for stratifying patients suffering from osteosarcoma, in order to identify patients having poor prognosis tumors. The invention also pertains to the use of an inhibitor of the PPARγ pathway as an antineoplastic treatment to improve the overall survival of patients with a poor prognosis osteosarcoma.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention concerns a novel in vitro assay for determining the invasive ability of brain tumour cells, in particular brain tumour stem cells. This new assay, called 3D invasion assay, is based on the analysis and comparison of the area of neurospheres grown in vitro into a Matrigel extracellular-like matrix. The invention also concerns the use of said assay for diagnosing metastatic brain tumour in subjects, for determining its prognosis, as well as for the monitoring, for the stratification, for identifying subjects at risk of metastasis, and/or predicting the metastasis-associated risk in subjects diagnosed with brain tumour.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a method for in vitro determining if an individual having a renal cell cancer (RCC) is likely to respond to a treatment with an anti-PD1/PD-L1/PD-L2 Ab-based therapy, based on the analysis of the microbiota present in a stool sample from said individual. Twelve models useful to perform the above method are disclosed, as well as tools designed to easily perform this method.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• G06F 17/18 - Complex mathematical operations for evaluating statistical data

Abstract

The present invention relates to the fields of medicine and in particular cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cells, in particular cancer cells, or changing the immunopeptidome, in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a therapy in a subject in need thereof. The invention also discloses methods for treating a disease, in particular cancer, for preventing or treating cancer metastasis and/or cancer recurrence, in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6813 - Hybridisation assays

Abstract

The present invention relates to the combined use of a neuropilin-1 (Nrp-1) neutralizing agent and of a programmed cell death-1 (PD-1) neutralizing agent for killing cancer cells, typically for treating cancer, as well as to corresponding pharmaceutical compositions and kits, and to corresponding diagnostic and therapeutic methods. The invention further relates to in vitro, ex vivo and in vivo methods for detecting CD8+ TILs capable of recognizing cancer cells, for predicting the response of a subject to anti-PD-1 treatment of cancer, and for identifying a subject who responds therapeutically to a treatment of cancer with an antibody combination therapy comprising anti-Nrp-1 and anti-PD-1 antibodies.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and/or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides fmegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, or B7-2 inhibitor.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/741 - Probiotics
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The present invention provides novel, easy-to-monitor and sensitive parameters, biomarkers and methods for the prediction of SARS-CoV-2 patients outcome, allowing in particular an early identification of patients evolving towards severe COVID-19 forms. The examples presented in the application show that a calprotectin-driven emergency myelopoisis in patients undergoing a switch toward a severe form of COVID 19 generates an innate immune cell signature of severe COVID-19. More precisely, the present inventors have found that the amount of CD14low/CD16+ monocytes, of HLA-DRlowclassical monocytes and of CD16lowneutrophils can independently or concomitantly be used as biomarkers of the severity of betacoronavirus infection, before the switch to the severe form of the infection (and related painful symptoms) actually occurs. The methods of the invention comprise the quantification, in a biological sample from an infected subject, of the amount of these immune cells. In addition, the Inventors have observed a surprising burst of calprotectin levels in COVID-19 patients that are undergoing a switch toward a severe disease. They therefore propose to use calprotectin plasma level as a biomarker of COVID-19 switch to severe form, and also as a therapeutic target for alleviating the disease symptoms.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/74 - Major histocompatibility complex [MHC]
• C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells
• C12N 5/0786 - MonocytesMacrophages
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The inventors herein show that purinergic receptors regulate the conversion of macrophage pro-inflammatory reprogramming into anti-inflammatory phenotype in patients suffering from COVID-19 disease. Moreover, they show that P2Y receptor agonists repress NLRP3 inflammasome-dependent IL-1b secretion, but also impair the replication and the cytopathogenic effects of SARS-CoV-2. These results therefore suggest that some purinergic receptors agonists can treat acute lung injury and respiratory disease that are associated with SARS-CoV-2 infection. In addition, their results show that antagonists of the purinergic receptors P2X impair the replication of said virus. The present invention therefore proposes to use purinergic receptors modulators and NLR3-P2Y2R immune checkpoint modulators to treat patients suffering from a virus-induced acute respiratory distress syndrome.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to the field of medical devices, more particularly the field of devices for extracting circulating molecules from the blood of a mammal, and to the therapeutic uses thereof, in particular in the treatment of sepsis, of cytokine release syndrome and/or of any other form of systemic inflammatory response or cytokine storm, caused by bacterial, parasitic, fungal or viral infections, in particular caused by a viral infection, for example coronaviruses with human respiratory tract tropism.

IPC Classes  ?

• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation

Abstract

E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to a method for identifying compounds useful for the treatment of cancer, based on assessing the ability of the compound to modulate the interaction between the AIF protein and the CHCHD4 protein.

IPC Classes  ?

• G01N 33/547 - Synthetic resin with antigen or antibody attached to the carrier via a bridging agent
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C07K 19/00 - Hybrid peptides

Abstract

The present invention relates to methods and compositions for the care of breast cancer, from diagnosis to treatment management. The inventors show that LINC01087 downregulation contributes to a more aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of triple-negative breast cancer. The inventors show that LINC01087 upregulation contributes to a less aggressive phenotype of BC, and could represents a novel and promising specific biomarker for the diagnosis of luminal BCs. The invention relates to a method comprising the steps of: i) determining the expression level of the long intergenic non-coding RNA 01087 (LINC01087) in a sample obtained from the subject, and ii) comparing the expression level determined at step i) with a predetermined reference value, wherein detecting difference between the expression level determined at step i) and the predetermined reference value is indicative of an aggressive TNBC or less aggressive luminal BCs.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A system for transporting persons with reduced mobility includes a chassis having two lateral cross members, a device for connecting to an IV pole including a rod and a wheeled support attached to an end of the rod, the connection device including an attachment support fixed to the chassis, a coupling element designed to be solidly fixed to the rod, a member for connecting the coupling element to the attachment support, a lateral stop attached to at least one of the cross members, the lateral stop being built and arranged to brace the wheeled support in relation to the chassis and to position the IV pole laterally in relation to the transportation system.

IPC Classes  ?

• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• A61G 5/10 - Parts, details or accessories

Abstract

The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 35/00 - Antineoplastic agents

Abstract

A freeze-dried powder for preparing a thermogel comprising: - from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; - from 40% to 85% of one or more poloxamer; and - from 0,1% to 20% of one or more carbohydrate compound.

IPC Classes  ?

• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/06 - OintmentsBases therefor
• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 35/00 - Antineoplastic agents
• A61K 9/51 - Nanocapsules
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61K 33/24 - Heavy metalsCompounds thereof

Abstract

The present invention relates to a water-in-oil emulsion comprising a continuous oil phase and an aqueous phase dispersed in the form of drops, the said aqueous phase comprising polyester-based nanoparticles and at least one therapeutic agent.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to novel therapeutic combinations comprising an oxazaphosphorine derivative and an immune checkpoint modulator for the treatment or the prevention of cancers.

IPC Classes  ?

• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• A61K 31/664 - Amides of phosphorus acids
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention pertains to the use of bacteria selected amongst Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum for inducing immunostimulation in a patient in combination with an anti-cancer immunotherapy with an immune checkpoint inhibitor (ICI) and/or a tyrosine kinase inhibitor (TKI). The invention also relates to methods for assessing the probability that a patient respond to a treatment with an ICI and/or a TKI, based on measuring the relative abundances of immunotolerant bacterial species (Clostridium hathewayi, Clostridium clostridioforme and Clostridium boltae) and/or immunostimulatory bacterial species (Akkermansia muciniphila, Bacteroides salyersiae, Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum) in the patient's gut microbiota.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12R 1/01 - Bacteria or actinomycetales
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to the field of nanomedicine, in particular for treating cancers. The present disclosure more specifically provides new methods of treating undesirable M2-polarized macrophages and/or inducing M1 macrophage polarization in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of nanoparticles containing metallic elements.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61P 35/00 - Antineoplastic agents
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 37/08 - Antiallergic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The present inventors have demonstrated that it is possible to control the secretory profile and phagocytosis function of pro-inflammatory macrophages, notably after irradiation on injured sites, by silencing the expression of a tumor suppressor gene called DUOX1 (dual oxidase 1). They therefore propose to inhibit the expression of the DUOX1 gene or the activity of the DUOX1 enzyme in tumor-associated macrophages for inducing a strong anti-tumor effect. They also propose to combine this treatment with a radiotherapy treatment, as said treatment is potentiated when DUOX1 is inhibited.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/12 - Ketones
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention is drawn to the use of Minaprine dihydrochloride and analogs thereof, for reducing tumor growth when administered to a patient suffering from cancer.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 35/00 - Antineoplastic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

in vivoin vivo, delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• C12N 5/0786 - MonocytesMacrophages
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention proposes a radiomics-based biomarker for detecting the presence and the density of tumor infiltrating CD8 T-cells in a solid tumor without having to use any biopsy of said tumor. The invention also proposes to use this information to assess the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to prognose the survival and/or the treatment efficiency of cancer patients treated with immunotherapy such as anti-PD-1/PD-L1 monotherapy.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G06T 7/00 - Image analysis
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising said oncolytic virus and said one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and said one or more immune checkpoint modulator(s).

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/741 - Probiotics
• A61K 39/02 - Bacterial antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to the prognosis and treatment of colon cancer. In particular, the present invention concerns the role of intestinal microbiota in the anticancer immune response elicited by ileal enterocytes succumbing to apoptosis, and provides immunogenic compositions for treating colorectal cancer (CRC), as well as signatures for prognosing CRC evolution.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 1/20 - BacteriaCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that proposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF), secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL, and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis, a secondary MDS or an AML. It also discloses a treating method for delaying MPN worsening, said treating method involving the inhibition of the ATG2B and GSKIP duplicated genes.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A pharmaceutical liquid suspension comprising: temozolomide or a salt thereof; at least one agent controlling the solid state of temozolomide in suspension; a pharmaceutically acceptable liquid vehicle; and optionally at least one acid in a quantity so that the pH of the composition is below 5; or a powder blend for reconstituting said suspension, is provided.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 9/08 - Solutions
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Although tumor-associated macrophages have been extensively studied in the control of response to radiotherapy, the molecular mechanisms involved in the ionizing radiation-mediated activation of macrophages remain elusive. Here the present inventors show that ionizing radiation induces the expression of interferon-regulatory factor 5 (IRF5) promoting thus macrophage activation toward a pro-inflammatory phenotype. They reveal that the activation of the Ataxia telangiectasia mutated (ATM) kinase is required for ionizing radiation-elicited macrophage activation, but also for macrophage reprogramming after treatments with γ-interferon, lipopolysaccharide or chemotherapeutic agent (such as cis-platin), underscoring the fact that the kinase ATM plays a central role during macrophage phenotypic switching toward a proinflammatory phenotype. They further demonstrate that NADPH oxidase 2 (NOX2)-dependent ROS production is upstream to ATM activation and is essential during this process. They also report that hypoxic conditions and the inhibition of any component of this signaling pathway (NOX2, ROS and ATM) impairs pro-inflammatory activation of macrophages and predicts a poor tumor response to preoperative radiotherapy in locally advanced rectal cancer. Altogether, these results identify a novel signaling pathway involved in macrophage activation that may enhance effectiveness of radiotherapy through the re-programming of tumor infiltrating macrophages.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C07K 14/80 - Cytochromes

Abstract

The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia.

IPC Classes  ?

• A61P 7/06 - Antianaemics
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 38/20 - Interleukins
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Abstract

The present invention relates to the combined use of a neuropilin-1 (Nrp-1) neutralizing agent and of a programmed cell death-1 (PD-1) neutralizing agent for killing cancer cells, typically for treating cancer, as well as to corresponding pharmaceutical compositions and kits, and to corresponding diagnostic and therapeutic methods. The invention further relates to in vitro, ex vivo and in vivo methods for detecting CD8+ TILs capable of recognizing cancer cells, for predicting the response of a subject to anti-PD-1 treatment of cancer, and for identifying a subject who respond therapeutically to a treatment of cancer with an antibody combination therapy comprising anti-Nrp-1 and anti-PD-1 antibodies.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses